Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma

References

• Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–7
   PubMed Web of Science ®Google Scholar
• Olavarria E, Kanfer EJ. Selection and use of chemotherapy with hematopoietic growth factors for mobilization of peripheral blood progenitor cells. Curr Opin Hematol 2000; 7: 191–6
   PubMed Web of Science ®Google Scholar
• Boiron JM, Marit G, Faberes C, et al. Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF). Bone Marrow Transplant 1993; 12: 49–55
   PubMed Web of Science ®Google Scholar
• Kotasek D, Shepherd KM, Sage RE, et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–7
   PubMed Web of Science ®Google Scholar
• Marit G, Thiessard F, Faberes C, et al. Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation in multiple myeloma patients: a monocentric study. Leukemia 1998; 12: 1447–56
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Hegenbart U, Haas R, Hunstein W. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691–7
   PubMed Web of Science ®Google Scholar
• Fitoussi O, Perreau V, Boiron JM, et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837–42
   PubMed Web of Science ®Google Scholar
• Jantunen E, Putkonen M, Nousiainen T, et al. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347–51
   PubMed Web of Science ®Google Scholar
• Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT, European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–23
   PubMed Web of Science ®Google Scholar
• Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547–55
   PubMed Web of Science ®Google Scholar
• Haas R, Mohle R, Fruhauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787–94
   PubMed Web of Science ®Google Scholar
• Tricot G, Jagannath S, Vesole D, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588–96
   PubMed Web of Science ®Google Scholar
• Alegre A, Tomas JF, Martinez-Chamorro C, et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997; 20: 211–7
   PubMed Web of Science ®Google Scholar
• Rowlings PA, Bayly JL, Rawling CM, et al. A comparison of peripheral blood stem cell mobilisation after chemotherapy with cyclophosphamide as a single agent in doses of 4 g/m2 or 7 g/m2 in patients with advanced cancer. Aust NZ J Med 1992; 22: 660–4
   PubMedGoogle Scholar
• Demuynck H, Delforge M, Verhoef G, et al. Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF. Br J Haematol 1995; 90: 384–92
   PubMed Web of Science ®Google Scholar
• Prince HM, Imrie K, Sutherland DR, et al. Peripheral blood progenitor cell collections in multiple myeloma: predictors and management of inadequate collections. Br J Haematol 1996; 93: 142–5
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495–502
   PubMed Web of Science ®Google Scholar
• Corso A, Arcaini L, Caberlon S, et al. A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica 2002; 87: 1041–5
   PubMed Web of Science ®Google Scholar
• Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34+ cells in elderly patients (>/ = 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413–23
   PubMed Web of Science ®Google Scholar
• Guba SC, Vesole DH, Jagannath S, et al. Peripheral stem cell mobilization and engraftment in patients over age 60. Bone Marrow Transplant 1997; 20: 1–3
   PubMed Web of Science ®Google Scholar
• Mehta J, Singhal S, Gordon L, et al. Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells. Bone Marrow Transplant 2002; 29: 563–7
   Google Scholar
• Yang SM, Liu KY, Lu DP. [Comparison of the effect of Cobe Spectra and Fenwal CS 3000 plus blood cell separators in collection of peripheral blood stem cell components.]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2005; 13: 245–9
   Google Scholar
• Hiwase DK, Schwarer AP, Bollard G , et al. Factors influencing collection of peripheral blood stem cells (PBSC). In: Haematology Society of Australasia and New Zealand Annual Meeting. Sydney: 2005. Abstract no 135. Published on HSANZ website, under resources and 2005 sydney.
   Google Scholar
• Gojo I, Guo C, Sarkodee-Adoo C, et al. High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Bone Marrow Transplant 2004; 34: 69–76
   PubMed Web of Science ®Google Scholar
• Min YJ, Kim SW, Suh C, et al. The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF. J Korean Med Sci 2000; 15: 49–52
   PubMedGoogle Scholar